Edgar Charlee
Fibrosis R&D
Optimize Courier
Philippines
Biography
Edgar leads clinical development for BMS-986036, Bristol-Myers Squibb’s pegylated FGF21 asset. He is responsible for global clinical development of BMS-986036, as well for contributing to the development strategy for other liver fibrosis assets. Edgar joined BMS in 2015 As leader of the clinical development team, Edgar sets therapeutic strategy, defines clinical plans, and designs Phase 0-3 trials.
Research Interest
clinical development
